Eman M Shorog

Dr. Eman M Shorog

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Mansour A MahmoudMansour A Mahmoud
Mansour A Mahmoud
AIAlnada Ibrahim
Alnada Ibrahim
HFHaifa Abdulrahman Fadil
Haifa Abdulrahman Fadil
AAAli Alalawi
Ali Alalawi
FAFaris Alnezary
Faris Alnezary
RARawan Alghamdi
Rawan Alghamdi
Background and Objectives: Chronic kidney disease (CKD) poses a significant risk for end-stage renal disease (ESRD), cardiovascular diseases, and premature death. The study aims to assess CKD knowledge and predictive variables among the general public. Materials and Methods: A cross-sectional study was conducted among the general public in Al Medina Al-Munawara, Saudi Arabia, utilizing a 21-item questionnaire-based approach over a 4-month period from January 2023 to April 2023. The developed questionnaire was validated for readability by experts and refined in light of the feedback received from the experts and the final version was prepared. The reliability of the questionnaire was 0.71, which shows an acceptable level of internal consistency. The data analysis was performed using IBM SPSS software (version 25). Results: A total of 777 complete surveys were received after applying the exclusion criteria. The study results revealed that the majority of the respondents had poor knowledge 505 (65%), 203 (26.1) had moderate knowledge, and 69 (8.9%) had good knowledge. Gender (p = 0.004), age (<0.001), education level (p = 0.039), marital status (p = 0.003), and occupation (p = 0.002) play significant roles in shaping participants’ knowledge levels regarding CKD. Lower odds of good knowledge were associated with females with an OR (95% CI) of 0.448 (0.263–0.764) and intermediate or higher secondary school level of education displayed an OR (95% CI) of 0.39 (0.18–0.89). Higher odds of good knowledge levels were associated with the age group of 18–27 with an OR (95% CI) of 5.077 (1.21–21.38) and being employed with an OR of 3.555 (1.04–12.21). Conclusions: A significant proportion of respondents had poor knowledge about CKD. Several demographic factors were associated with CKD knowledge. Further research is needed to explore these knowledge disparities and develop targeted interventions to improve CKD knowledge among the general public.

14 December 2024 in Brain Research
Verified
Journal Article
Closed access
SYSabina Yasmin
Sabina Yasmin
SASumel Ashique
Sumel Ashique
TTTahreen Taj
Tahreen Taj
AGAshish Garg
Ashish Garg
JDJoy Das
Joy Das
Mohammad Yousuf AnsariMohammad Yousuf Ansari
Mohammad Yousuf Ansari

22 October 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
VEVigneshwaran Easwaran
Vigneshwaran Easwaran
ESEman M Shorog
Eman M Shorog
AAAlmaha Ali Alshahrani
Almaha Ali Alshahrani
AMAsif Ansari Shaik Mohammad
Asif Ansari Shaik Mohammad
MMMohammad J S Mantargi
Mohammad J S Mantargi
SASultan Alshahrani
Sultan Alshahrani
Despite the availability of human papillomavirus (HPV) vaccines and screening facilities at various health centers in Saudi Arabia, the annual death rate due to cervical cancer is high. Therefore, knowledge and awareness are essential for self-care and educating others, particularly among healthcare students. The present descriptive, cross-sectional study explored female pharmacy students’ knowledge, attitudes, and practices related to cervical cancer. A total of 140 students participated in the survey. The survey was conducted for the period between April 2022 to September 2023. We observed a good knowledge score and positive attitudes among 8.5% and 93.5% of participants, respectively. A total of 10% of the study participants reported good practice scores. Most participants had never been screened for cervical cancer (94.3%). Among the non-screened subjects, feeling healthy and lacking information were the participants’ significant reasons for not screening for cervical cancer. A positive history of cancer related to smoking significantly impacted the knowledge score (p = 0.050). The current study reveals that healthcare awareness programs for cervical cancer and HPV vaccination are necessary at the level of educational institutions to improve public health.

15 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SUShehla Nasar Mir Najib Ullah
Shehla Nasar Mir Najib Ullah
Obaid AfzalObaid Afzal
Obaid Afzal
AAAbdulmalik Saleh Alfawaz Altamimi
Abdulmalik Saleh Alfawaz Altamimi
MAManal A. Alossaimi
Manal A. Alossaimi
WAWaleed H. Almalki
Waleed H. Almalki
JSJ. K. Singh
J. K. Singh
Non-small-cell lung cancer (NSCLC) mortality and new case rates are both on the rise. Most patients have fewer treatment options accessible due to side effects from drugs and the emergence of drug resistance. Bedaquiline (BQ), a drug licensed by the FDA to treat tuberculosis (TB), has demonstrated highly effective anti-cancer properties in the past. However, it is difficult to transport the biological barriers because of their limited solubility in water. Our study developed a UPLC method whose calibration curves showed linearity in the range of 5 ng/mL to 500 ng/mL. The UPLC method was developed with a retention time of 1.42 and high accuracy and precision. Its LOQ and LOD were observed to be 10 ng/mL and 5 ng/mL, respectively, whereas in the formulation, capmul MCM C10, Poloxamer 188, and PL90G were selected as solid lipids, surfactants, and co-surfactants, respectively, in the development of SLN. To combat NSCLC, we developed solid lipid nanoparticles (SLNs) loaded with BQ, whereas BQ suspension is prepared by the trituration method using acacia powder, hydroxypropyl methylcellulose, polyvinyl acrylic acid, and BQ. The developed and optimized BQ-SLN3 has a particle size of 144 nm and a zeta potential of (−) 16.3 mV. whereas BQ-loaded SLN3 has observed entrapment efficiency (EE) and loading capacity (LC) of 92.05% and 13.33%, respectively. Further, BQ-loaded suspension revealed a particle size of 1180 nm, a PDI of 0.25, and a zeta potential of −0.0668. whereas the EE and LC of BQ-loaded suspension were revealed to be 88.89% and 11.43%, respectively. The BQ-SLN3 exhibited insignificant variation in particle size, homogeneous dispersion, zeta potential, EE, and LC and remained stable over 90 days of storage at 25 °C/60% RH, whereas at 40 °C/75% RH, BQ-SLN3 observed significant variation in the above-mentioned parameters and remained unstable over 90 days of storage. Meanwhile, the BQ suspension at both 25 °C (60% RH) and 40 °C (75% RH) was found to be stable up to 90 days. The optimized BQ-SLN3 and BQ-suspension were in vitro gastrointestinally stable at pH 1.2 and 6.8, respectively. The in vitro drug release of BQ-SLN3 showed 98.19% up to 12 h at pH 7.2 whereas BQ suspensions observed only 40% drug release up to 4 h at pH 7.2 and maximum drug release of >99% within 4 h at pH 4.0. The mathematical modeling of BQ-SLN3 followed first-order release kinetics followed by a non-Fickian diffusion mechanism. After 24 to 72 h, the IC50 value of BQ-SLN3 was 3.46-fold lower than that of the BQ suspension, whereas the blank SLN observed cell viability of 98.01% and an IC50 of 120 g/mL at the end of 72 h. The bioavailability and higher biodistribution of BQ-SLN3 in the lung tumor were also shown to be greater than those of the BQ suspension. The effects of BQ-SLN3 on antioxidant enzymes, including MDA, SOD, CAT, GSH, and GR, in the treated group were significantly improved and reached the level nearest to that of the control group of rats over the cancer group of rats and the BQ suspension-treated group of rats. Moreover, the pharmacodynamic activity resulted in greater tumor volume and tumor weight reduction by BQ-SLN3 over the BQ suspension-treated group. As far as we are aware, this is the first research to look at the potential of SLN as a repurposed oral drug delivery, and the results suggest that BQ-loaded SLN3 is a better approach for NSCLC due to its better action potential.

30 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RTRohit Tayal
Rohit Tayal
SYSabina Yasmin
Sabina Yasmin
SCSAMRAT CHAUHAN
SAMRAT CHAUHAN
TSThakur Gurjeet Singh
Thakur Gurjeet Singh
MSMonika Saini
Monika Saini
Mohammad Yousuf AnsariMohammad Yousuf Ansari
Mohammad Yousuf Ansari
Balancing the therapeutic advantages of a medicine with its possible risks and side effects is an important part of medical practice and drug regulation. When a drug is designed to treat a particular disease or medical condition ends up causing additional risks or side effects that lead to the development of other serious health problems, it can have detrimental consequences for patients. This article explores the correlation between persistent proton pump inhibitor (PPI) use and hypertension, a common cardiovascular ailment. While PPIs are beneficial in treating various gastrointestinal problems, their availability without a prescription has resulted in self-medication and long-term use without medical monitoring. Recent findings have revealed a link between long-term PPI usage and increased cardiovascular risks, particularly hypertension. This study investigates the intricate mechanisms underlying PPI’s effects, focusing on potential pathways contributing to hypertension, such as endothelial dysfunction, disruption of nitric oxide bioavailability, vitamin B deficiency, hypocalcemia, and hypomagnesemia. The discussion explains how long-term PPI use can disrupt normal endothelial function, vascular control, and mineral balance, eventually leading to hypertension. The article emphasizes the significance of using PPIs with caution and ongoing research to better understand the implications of these medications on cardiovascular health.

17 December 2025 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
PGPriyanka Gupta
Priyanka Gupta
BDBiplab Debnath
Biplab Debnath
SASumel Ashique
Sumel Ashique
MRMohhammad Ramzan
Mohhammad Ramzan
SYSabina Yasmin
Sabina Yasmin
Mohammad Yousuf AnsariMohammad Yousuf Ansari
Mohammad Yousuf Ansari